InVera Medical

Executive Summary

InVera Medical is an Irish medical device company headquartered in Galway, founded in 2015, focusing on cardiovascular infusion systems. The company's lead product, the InVera Infusion device, recently achieved CE Marking approval under the European Medical Device Regulation (MDR 2017/745) from BSI (Notified Body 2797). This approval authorizes commercial sale and distribution within the European Union, marking a significant regulatory milestone. However, the device remains investigational in the United States and other territories, with no FDA clearance or commercial approval to date. The company operates at a pre-clinical stage, although the CE Mark suggests readiness for early commercialization in Europe. No funding or revenue data is publicly available, and the company has limited profile visibility, indicating it may be early in its commercial journey or operating under the radar. The CE Mark provides InVera Medical with a clear pathway to generate initial revenue in the EU, potentially in a niche cardiovascular infusion market. The company's success will hinge on its ability to execute a commercial launch, secure distribution partnerships, and navigate the US regulatory pathway. Key risks include the lack of US approval, limited financing visibility, and competition from established cardiovascular device players. Given the early stage and limited public information, conviction is moderate. Near-term catalysts could include first EU sales, initiation of US clinical trials, or strategic partnerships, which would validate the technology and de-risk the investment thesis.

Upcoming Catalysts (preview)

• Q4 2026First commercial sales in the EU75% success
• Q2 2027US FDA Investigational Device Exemption (IDE) submission50% success
• TBDStrategic partnership or distribution agreement60% success